[1] Tsantes A G, Papadopoulos D V, Vrioni G, et al. Spinal Infections: An Update[J]. Microorganisms, 2020,8(4).
[2] Lazzeri E, Bozzao A, Cataldo M A, et al. Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults[J]. Eur J Nucl Med Mol Imaging, 2019,46(12):2464-2487.
[3] Fragio G J, Gonzalez M R, Salavert L M, et al. Vertebral osteomyelitis: Clinical, microbiological and radiological characteristics of 116 patients[J]. Med Clin (Barc), 2020.
[4] Russo A, Graziano E, Carnelutti A, et al. Management of vertebral osteomyelitis over an eight-year period: The UDIPROVE (UDIne PROtocol on VErtebral osteomyelitis)[J]. Int J Infect Dis, 2019,89:116-121.
[5] Kamal A M, El-Sharkawi M M, El-Sabrout M, et al. Spondylodiscitis: experience of surgical management of complicated cases after failed antibiotic treatment[J]. SICOT J, 2020,6:5.
[6] Bornemann R, Rossler P, Jacobs C, et al. Spondylitis - Spondylodiscitis - an Update [J]. From Orthop Accident, 2019,157 (2): 132-143.
[7] Chang W S, Ho M W, Lin P C, et al. Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan[J]. J Microbiol Immunol Infect, 2018,51(2):235-242.
[8] Weissman S, Parker R D, Siddiqui W, et al. Vertebral osteomyelitis: retrospective review of 11 years of experience[J]. Scand J Infect Dis, 2014,46(3):193-199.
[9] Kang S J, Jang H C, Jung S I, et al. Clinical characteristics and risk factors of pyogenic spondylitis caused by gram-negative bacteria[J]. PLoS One, 2015,10(5):e127126.
[10] Aljawadi A, Jahangir N, Jeelani A, et al. Management of Pyogenic Spinal Infection, review of literature[J]. J Orthop, 2019,16(6):508-512.
[11] Pola E, Taccari F, Autore G, et al. Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients[J]. Eur Spine J, 2018,27(Suppl 2):229-236.
[12] Nickerson E K, Sinha R. Vertebral osteomyelitis in adults: an update[J]. Br Med Bull, 2016,117(1):121-138.
[13] Sato K, Yamada K, Yokosuka K, et al. Pyogenic Spondylitis: Clinical Features, Diagnosis and Treatment[J]. Kurume Med J, 2019,65(3):83-89.
[14] Lee C Y, Wu M H, Cheng C C, et al. Comparison of gram-negative and gram-positive hematogenous pyogenic spondylodiscitis: clinical characteristics and outcomes of treatment[J]. BMC Infect Dis, 2016,16(1):735.
[15] Park K H, Cho O H, Jung M, et al. Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria[J]. J Infect, 2014,69(1):42-50.
[16] Kim D Y, Kim U J, Yu Y, et al. Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics[J]. Open Forum Infectious Diseases, 2020,7(6).
[17] Berbari E F, Kanj S S, Kowalski T J, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults[J]. Clinical Infectious Diseases, 2015,61(6):e26-e46.
[18] Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial[J]. Lancet, 2015,385(9971):875-882.
[19] Park K H, Cho O H, Lee J H, et al. Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertebral Osteomyelitis at Low Risk and High Risk of Recurrence[J]. Clin Infect Dis, 2016,62(10):1262-1269.
[20] Babic M, Simpfendorfer C S. Infections of the Spine[J]. Infect Dis Clin North Am, 2017,31(2):279-297.
[21] Issa K, Diebo B G, Faloon M, et al. The Epidemiology of Vertebral Osteomyelitis in the United States From 1998 to 2013[J]. Clin Spine Surg, 2018,31(2):E102-E108.
[22] Kwon J W, Hyun S J, Han S H, et al. Pyogenic Vertebral Osteomyelitis: Clinical Features, Diagnosis, and Treatment[J]. Korean J Spine, 2017,14(2):27-34.
[23] Pola E, Pambianco V, Autore G, et al. Minimally invasive surgery for the treatment of thoraco lumbar pyogenic spondylodiscitis: indications and outcomes[J]. Eur Rev Med Pharmacol Sci, 2019,23(2 Suppl):94-100.